Joachim V. C.
- Country
- Belgium
- Department
- Ophthalmology
Research Overview
- Efficacy and Safety Evaluation of Belzupacap Sarotalocan in Primary Indeterminate Lesions or Small Choroidal Melanoma: A Phase 3 Randomized Controlled Trial
- Phase 3 Randomized, Double-Masked, Placebo-Controlled Trial of Brepocitinib Tosilate in Adults with Active Non-Infectious Intermediate, Posterior, and Panuveitis
- A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
Data & Insights
Has run more than one trial at 17 of 70 partner sites.
Specializations
Ophthalmology Focus
The investigator specializes in treating non-infectious uveitis, with particular expertise in various anatomical forms including intermediate uveitis, posterior uveitis, and panuveitis.
- Non-anterior ocular inflammation
- Inflammatory eye disorders
- Autoimmune eye conditions
Their research interests center on innovative therapeutic approaches for managing complex ocular inflammatory conditions.
Immunology Research
The investigator focuses on immune-mediated ocular disorders, particularly exploring new therapeutic pathways in treating inflammatory eye conditions.
- Non-infectious inflammatory disorders
- Immune system modulation
- Chronic inflammation management
Their work emphasizes understanding and treating complex immunological mechanisms in ocular inflammation.
Therapeutic Innovation
The investigator's work encompasses evaluating novel treatments for inflammatory eye diseases, with a focus on advancing therapeutic options for patients with treatment-resistant conditions.
- Advanced therapeutic approaches
- Inflammatory disease management
- Novel treatment evaluation
Their research aims to expand treatment options for patients with complex ocular inflammatory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.